image credit- shutterstock
4D Path, a US-based company dedicated to personalising cancer care through a novel, physics-informed approach to predicting tumor response to therapy, has announced a collaboration with Japan's Daiichi Sankyo to develop next-generation predictive biomarkers in an antibody drug conjugate (ADC) clinical development programme.
ADCs are among the most promising therapeutic classes in oncology, yet there remains a significant unmet need for scalable biomarkers that predict which patients are most likely to benefit from increasingly complex regimens and combination therapies. This collaboration brings together 4D Path’s ability to compute biologically grounded, physics-informed treatment predictive biomarkers from routine pathology specimens with the ADC innovation leadership of Daiichi Sankyo.
Under the collaboration, 4D Path will apply its proprietary Q-Plasia OncoReader™ (QPOR™) platform to standard Hematoxylin and Eosin (H&E)-stained tumor biopsy slides to compute interpretable, quantitative biomarkers associated with cell-cycle deregulation and tumor microenvironment dynamics.
These biomarkers will be evaluated for their ability to identify patients most likely to benefit from the select ADC, helping enable more precise, non-invasive, and cost-effective patient selection, potentially improving response rates and accelerating clinical trials.
